- Open Access
The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3
© Agarwal et al; licensee BioMed Central Ltd. 2008
- Received: 24 April 2008
- Accepted: 07 August 2008
- Published: 07 August 2008
Germline and somatic inactivating mutations in the HRPT2 gene occur in the inherited hyperparathyroidism-jaw tumor syndrome, in some cases of parathyroid cancer and in some cases of familial hyperparathyroidism. HRPT2 encodes parafibromin. To identify parafibromin interacting proteins we used the yeast two-hybrid system for screening a heart cDNA library with parafibromin as the bait.
Fourteen parafibromin interaction positive preys representing 10 independent clones encoding actinin-2 were isolated. Parafibromin interacted with muscle alpha-actinins (actinin-2 and actinin-3), but not with non-muscle alpha-actinins (actinin-1 and actinin-4). The parafibromin-actinin interaction was verified by yeast two-hybrid, GST pull-down, and co-immunoprecipitation. Yeast two-hybrid analysis revealed that the N-terminal region of parafibromin interacted with actinins. In actin sedimentation assays parafibromin did not dissociate skeletal muscle actinins from actin filaments, but interestingly, parafibromin could also bundle/cross-link actin filaments. Parafibromin was predominantly nuclear in undifferentiated proliferating myoblasts (C2C12 cells), but in differentiated C2C12 myotubes parafibromin co-localized with actinins in the cytoplasmic compartment.
These data support a possible contribution of parafibromin outside the nucleus through its interaction with actinins and actin bundling/cross-linking. These data also suggest that actinins (and actin) participate in sequestering parafibromin in the cytoplasmic compartment.
- Actin Filament
- C2C12 Cell
- Pellet Fraction
- Glutathione Sepharose Bead
- Spectrin Repeat
Parafibromin is encoded by the HRPT2 gene located on chromosome 1q31 (OMIM# 145001 and 607393). HRPT2 inactivating mutations in the germline occur in the hyperparathyroidism-jaw tumor (HPT-JT) syndrome, characterized by hyperparathyroidism (parathyroid adenoma or carcinoma) (90%), fibrous-ossifying jaw tumors (30%), and bilateral renal cysts (10%) [1, 2]. Germline HRPT2 mutations have also been detected in some cases of familial hyperparathyroidism [1, 3, 4], and biallelic somatic inactivation of HRPT2 is common in parathyroid tumor of HPT-JT and in sporadic parathyroid cancer [5–7].
Parafibromin has three possible nuclear localization signals; it is predominantly found in the nucleus [8–16] and in the nucleolus . The C-terminal part of parafibromin (ORF = 531 amino acids) is homologous to yeast Cdc73p (ORF = 393 amino acids), an RNA polymerase II accessory protein . Analogous to the presence of yeast Cdc73p in the yeast Paf1 protein complex, parafibromin was found in the human and Drosophila PAF1 protein complex [10, 19–21]. Genetic interaction studies in Drosophila and protein interaction studies in mammalian cells have shown an interaction of parafibromin with β-catenin, mediating a functional association between Wnt signaling and the PAF1 complex .
The yeast two-hybrid system has been extensively used for the identification and analysis of protein-protein interactions [23, 24]. To isolate parafibromin interacting proteins we conducted a yeast two-hybrid library screen, and we discovered an interaction between parafibromin and muscle actinins.
Parafibromin interacting proteins
Yeast Two-hybrid Library Screening
Skeletal muscle actinin, alpha-2 (actinin-2)
Four and a half LIM-domains 2
Dystrophia myotonica protein kinase
Clathrin heavy chain like-1
Early endosome antigen 1
Yeast Two-hybrid Interaction† of Parafibromin Fused to Gal4DBD with Full-length Proteins Fused to Gal4AD
Activation Domain Fusion
GST pull-down and co-immunoprecipitation of parafibromin interacting proteins
The interaction of parafibromin with actinins was further characterized in vivo by co-immunoprecipitation of actinin-2 or actinin-3 from protein extracts of HEK293 cells transfected with parafibromin-myc-his or menin-myc-his together with FLAG-tagged actinin-2 or actinin-3. FLAG-actinin-2 and FLAG-actinin-3 co-precipitated with parafibromin-myc-his but not with menin-myc-his (Figure 1C).
Interacting regions of parafibromin and actinin
Actin filament bundling/cross-linking by actinin and parafibromin
Differentiation induced cytoplasmic localization of parafibromin with actinins
Localization of endogenous parafibromin with transfected actinin in the cytoplasm
One of the functional associations of parafibromin is with the PAF1 complex, involved in the regulation of transcriptional initiation and elongation in yeast, and based upon the presence of a C-terminal domain homologous to yeast Cdc73p [10, 19–21]. This function of parafibromin is also connected to the Wnt signaling pathway by interaction with β-catenin . In this interaction, parafibromin possibly recruits the PAF1 complex to β-catenin responsive genes thereby modulating the transcriptional output of β-catenin. In reporter assays, β-catenin mediated transcription could be regulated by Drosophila parafibromin (hyrax) but not by yeast Cdc73p . In Drosophila with mutant hyrax alleles, human or Drosophila parafibromin could rescue the lethal phenotype . The lethal phenotype of mutant hyrax alleles was not rescued by yeast Cdc73p. The presence of the N-terminal 350 amino acid region in human and Drosophila parafibromin that is not found in yeast Cdc73p suggests that, in addition to its Cdc73-associated function, parafibromin could possess other activities and/or functional associations.
Using the yeast two-hybrid approach, we report interaction of the N-terminus of parafibromin with muscle actinins. Multiple (n = 10) independent clones of actinin-2 were isolated in the yeast two-hybrid library screen, and the interaction was verified by other in vitro and in vivo methods suggesting a strong and significant interaction between parafibromin and actinin-2. Actinins (molecular mass ~100 kDa) are actin-binding proteins that are expressed in both muscle and non-muscle cells, and that cause bundling of actin filaments for cytoskeletal organization . Actinins also serve to link the cytoskeleton, membrane proteins, and signaling proteins [30, 31]. There are 4 alpha-actinins encoded by 4 different genes. The 4 proteins are highly homologous sharing 73–84% amino acid sequence identity . Actinin-1 and actinin-4 are abundant in non-muscle cells, forming actin filament bundles such as stress fibers. They are associated with calcium dependent membrane attachment, and with cell-cell and cell-matrix adherent junctions . In muscle cells, actinin-2 and actinin-3 are major structural components of striated muscle where they anchor actin filaments . Actinin-2 is expressed in all muscle cells, whereas actinin-3 expression is limited to a subset of fast twitch skeletal fibers. In our yeast two-hybrid assays, parafibromin selectively interacted with the two muscle actinins (actinin-2 and actinin-3) but not at all with the non-muscle actinins (Table 2).
Actinins are composed of three distinct domains. An N-terminal actin-binding domain, a central rod-shaped domain with 4 internal spectrin-like repeats required for anti-parallel dimerization, and a C-terminal calmodulin-like domain containing a pair of calcium-binding EF hands  (Figure 2B). The EF-hands in non-muscle actinins, actinin-1 and actinin-4, are functional (calcium sensitive) whereas the EF-hands in muscle actinins, actinin-2 and -3 are non-functional (calcium insensitive). All the library clones of actinin-2 interacting with parafibromin were truncated at the N-terminus thus lacking the actin-binding domain and most of the first spectrin repeat of actinins. Further deletion of the N-terminus including the second spectrin repeat prevented interaction with parafibromin. Similarly, actinin-3 lacking its C-terminal EF-hand domains allowed interaction with parafibromin, but further C-terminal deletion including the third and fourth spectrin repeat (but retaining the first and second spectrin repeat) impaired interaction with parafibromin. Therefore, parafibromin likely interacts with the region of actinin containing spectrin repeats 2, 3 and 4 (Figure 2B). The region of highest variability among all actinins is in spectrin repeats 3 and 4 (not shown in Figure 2B) . This could potentially explain why parafibromin interacts with muscle actinins and not with non-muscle actinins. Deletion of N-terminal 112 amino acids of parafibromin impaired actinin interaction. The N-terminal region of parafibromin minus its C-terminal Cdc73p homologous domain was sufficient for interaction with actinin (Figure 2A).
Actinins possess actin bundling and cross-linking activity [26, 27, 35]. In low speed actin sedimentation assays where actin filaments (F-actin) pellet only when they are arranged in higher order structures by cross-linking and/or bundling, just like actinin, to our surprise parafibromin was also capable of pelleting F-actin, indicating that parafibromin probably has inherent F-actin bundling or cross-linking activity. Moreover, despite parafibromin's predicted interaction with a part of the actinin dimerization region, parafibromin did not displace or disrupt actinin from F-actin bundles based on the observation that presence of parafibromin and actinin together appeared to slightly enhance the pelleting of F-actin (Figure 3B). This assay does not distinguish if the increased F-actin in the pellet fraction upon incubation of F-actin with actinin and parafibromin together was due to an increase in the number of F-actin bundles, or due to thicker bundles resulting from an increase in the number of F-actin filaments in individual bundles, or due to increased cross-linking. In yeast two-hybrid assays parafibromin did not interact with actin (Table 2). Parafibromin sequence analysis did not reveal any regions with significant homology to the several different actin-binding motifs that are found in actin-binding proteins .
Skeletal muscle myoblasts (such as modeled by C2C12 cells) can be induced to differentiate in mitogen-poor media to fuse and form multinucleate myotubes. This myogenic program is coupled to loss of cell proliferation and increase of differentiation. Actinins are important cytoskeletal structural proteins and their expression in the multinucleate myotubes increases upon induction of myotube formation . Parafibromin's accumulation in the cytoplasm coincides with the inhibition of proliferation and with the activation of differentiation. The co-localization of parafibromin and actinin in the cytoplasm could be unrelated to their direct interaction. But the changed compartmentalization in HEK293 cells of endogenous parafibromin to the cytoplasm upon actinin transfection (Figure 6) indicates that the observation in C2C12 cells is likely related to parafibromin-actinin interaction. Parafibromin-actinin interaction might be directly important for mechanical strength and structure of the actin cytoskeleton, or the interaction could mediate other regulatory functions. Actin and actinin could play a role in regulating parafibromin levels in the nucleus for modulating parafibromin's transcription associated functions. The transcription associated tumor suppressor function of parafibromin could require its migration from the nucleus to cytoplasm as in C2C12 cells. Actin has been implicated in regulating gene transcription through several mechanisms, one of which is a direct role in controlling the nucleo-cytoplasmic distribution of transcription factors (Reviewed in ). Therefore, this interaction could be important for regulating the activity, and sub-cellular localization of parafibromin. Our observations in C2C12 cells also suggest other new aspects of parafibromin action such as a possible role in organization of the cytoskeleton and in myotube differentiation. We have investigated parafibromin-actinin interaction in muscle cells. The functional consequence of parafibromin-actinin interaction in cells affected in HPT-JT – parathyroid cells, bone cells, or renal cells – remains to be determined.
In C. elegans, RNAi against HRPT2 caused defects in the proper formation of polar bodies, pronuclei and mitotic nuclei indicating that HRPT2 is important for the proper completion of both meiosis and mitosis . The phenotype analysis also suggested that the HRPT2 product is important for microtubule-based function in the early embryo. Perhaps, this function of parafibromin is also linked to its association with actinins.
Our study does not directly address parafibromin's participation in the PAF-1 complex or the physiological function of parafibromin in the nucleus or cytoplasm, but the observation that interaction with actinins (and actin filament bundling/cross-linking) likely occurs when parafibromin accumulates in the cytoplasm suggests that a biological activity of parafibromin might be controlled by signals that promote its cytoplasmic accumulation. Further studies to recognize such signals and their consequences could provide insight into the functions of parafibromin in normal physiology and in tumorigenesis.
Anti-parafibromin rabbit polyclonal antibody GRAPE was generated against a synthetic peptide (human parafibromin amino acid 262–299), and then affinity purified . Mouse monoclonal anti-alpha-actinin clone BM-75.2 and mouse anti-FLAG M2 antibodies were from Sigma; rabbit anti-myc and mouse anti-myc antibodies were from Upstate. Rabbit IgG, mouse IgG, and HRP-conjugated secondary antibodies were from Santa Cruz Biotechnologies. Anti-rabbit secondary antibody conjugated to Texas Red and anti-mouse secondary antibody conjugated to fluorescein isothiocyanate were from Jackson ImmunoResearch Laboratories. Rabbit polyclonal affinity-purified peptide antibodies against actinin-2 and against actinin-3 were a gift from Dr. Neal Epstein of NHLBI, NIH.
Mammalian cell culture and transfection
HEK293, HeLa, and C2C12 cell lines were obtained from American Type Culture Collection and grown in complete Dulbecco's modified Eagle's medium (DMEM containing high glucose, 2 μM glutamine, 1× concentration of antibiotic-antimycotic mix, and 10% fetal bovine serum) at 37°C in a humidified incubator containing 5% CO2. For differentiation of C2C12 myoblasts into myotubes, sub-confluent cells were grown for 4–6 days in differentiation medium (DMEM containing high glucose, 2 μM glutamine, 1× concentration of antibiotic-antimycotic mix, and 2% horse serum). Transient transfection was carried out with Polyfect (Qiagen) as per the manufacturer.
Yeast two-hybrid assay
Yeast reporter strains for yeast-two-hybrid experiments were Y190 (Clontech), MaV203 (Invitrogen), or EGY48 (kind gift from Dr, Erica Golemis, Wayne State University). Matchmaker two-hybrid system II and the Mammalian Matchmaker two-hybrid assay kit were from Clontech.
The coding region of HRPT2 was amplified from human leukocyte marathon cDNA (Clontech) with primers containing restriction enzyme sites using Turbo Pfu (Stratagene), and cloned into the Gal4 DNA-binding domain (Gal4DBD)-fusion vector pAS2-1 in-frame with the Gal4DBD. All primers and PCR conditions in this study are available upon request.
pAS2-1-parafibromin was used as a bait to screen a yeast two-hybrid human heart cDNA library in the Gal4-Activation Domain (AD)-fusion vector pACT-2 (Clontech) by sequential transformation in Y190. The bait Gal4DBD-parafibromin did not have any transcription-activating property nor did it interact with Gal4AD alone or with Gal4AD-T-antigen. Transformed yeast were grown in 50 large (150 mm) petri dishes of SD -Trp, -Leu, -His selection media containing 20 mM 3-Aminotriazole (3AT) to control the leaky nature of the His+ phenotype. Colonies positive for growth were restreaked and tested for the second reporter LacZ (β-galactosidase (β-gal) activity) by colony filter lift assay (yeast protocols handbook, Clontech). Plasmids from colonies positive for growth in selection media and positive for β-gal activity (blue), corresponding to library plasmid expressing parafibromin interacting proteins, were retrieved by using the yeast DNA isolation system (Stratagene). These pACT-2 library plasmids were retransformed into yeast competent cells (MaV203) together with pAS2-1-parafibromin to confirm the protein-protein interaction. None of the library positives were self-activating nor did they interact with Gal4DBD-p53 or Gal4DBD alone. Plasmids that still were positive for parafibromin interaction after this testing were sequenced with vector primers at both ends of the insert.
Other constructs in the pAS2-1 or pACT-2 were generated by cloning in-frame inserts. Full-length coding region of actinin-1, actinin-2, actinin-3, actinin-4, desmin, FHL-1, FHL2, FHL-3, FHL-4, and α-actin was amplified using marathon cDNA (Clontech) from human skeletal muscle (actinin-2, actinin-3, desmin, FHL-1, FHL2, FHL-3, and α-actin), human brain (actinin-1 and actinin-4), or mouse testis (FHL-4), with primers containing restriction enzyme sites using Turbo Pfu (Stratagene), and cloned into pACT-2. Inserts containing various deletions from the N- and C- terminus of parafibromin or actinin-3 were generated by PCR amplification using appropriate primers, with pAS2-1-parafibromin or pACT-2-actinin-3 as the template, and cloned into pAS2-1 or pACT-2, respectively. For testing interaction of parafibromin deletion constructs, actnin-3 was used because the interaction of full-length actinin-3 with parafibromin was similar but slightly stronger than with full-length actinin-2. The LexA-DBD-parafibromin construct pCM031 and the Gal4AD-β-catenin construct pRH95 were provided by Dr. Christian Mosimann, University of Zurich .
Interaction of fusion-proteins expressed by the pAS2-1 and pACT-2 constructs were tested by transforming into yeast competent cells (MaV203). Yeast colonies growing on plates containing SD -Trp, -Leu selection media were tested for β-gal activity by colony filter lift assay. None of the pACT-2 constructs were self-activating nor did they interact with Gal4DBD-p53 or Gal4DBD alone. The interaction of parafibromin in LexA-DBD vector with β-catenin in Gal4-AD vector was tested in the yeast strain EGY48 using the LexA reporter pSH18-34 and SD -Trp, -Leu, -Ura selection media.
To verify the expression of fusion proteins in yeast, protein extracts were analyzed by western blot .
GST pull-down assay
The full-length coding regions of actinin-2, actinin-3, desmin or FHL2 were sub-cloned from the yeast two-hybrid vector pACT-2 into the GST-fusion vector pGEX5X-2 (Amersham-Pharmacia). The coding region of parafibromin was amplified from leukocyte marathon cDNA and cloned into the myc-tag fusion vector pcDNA3.1(-)-myc-his-A (Invitrogen) in-frame with a downstream myc-his-tag. In order to generate an in-frame fusion of parafibromin at the C-terminus with the myc-his tag, the parafibromin stop codon was changed from TGA to AGA in the reverse primer.
GST or GST-fusion proteins (GST-actinin-2, GST-actinin-3, GST-desmin or GST-FHL2) were expressed in bacteria in the E. coli BL21-PRIL strain (Stratagene), and purified on glutathione sepharose beads (Amersham-Pharmacia) as described . Similar amounts of GST alone, or GST-fusion proteins coupled to glutathione sepharose beads were incubated overnight at 4°C with whole cell protein extracts from HEK293 cells transfected with a plasmid expressing parafibromin-myc-his. The beads were washed thoroughly 5 times with the lysis buffer-1 (TBS containing 0.1% Triton X-100 and 1 mM DTT) that was used for preparing protein extracts, and resuspended in protein loading buffer. The bound parafibromin was detected by western blot with an anti-myc antibody.
The full-length coding region of actinin-2 and actinin-3 was sub-cloned from the yeast two-hybrid vector pACT-2 into the FLAG-fusion vector pCMVtag2C (Stratagene). The plasmid construct expressing parafibromin-myc-his was described above, and the menin-myc-his construct was previously described . Before their use in co-immunoprecipitation (Co-IP) experiments, the FLAG-actinin-2, FLAG-actinin-3, and parafibromin-myc-his expression was verified by transfecting HEK293 cells and analyzing whole cell protein extracts by western blot using specific antibodies (data not shown).
HEK293 cells were transfected with plasmids expressing FLAG-actinin-2 or FLAG-actinin-3 together with plasmids expressing parafibromin-myc-his or menin-myc-his. Whole cell protein extracts were prepared 48 h after transfection in lysis buffer-2 (20 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, and 0.1% deoxycholate). Protein extracts were used for immunoprecipitation as described with 4 μg of rabbit anti-myc antibody . Actinin and parafibromin were detected by western blot with anti- FLAG or mouse anti-myc antibodies, respectively.
Actin sedimentation assay
The full-length coding region of parafibromin was sub-cloned from the yeast two-hybrid vector pAS2-1 into the GST-fusion vector pGEXIIT (Amersham-Pharmacia). The plasmid construct expressing GST-RPA2 was previously described . GST, GST-parafibromin, or GST-RPA2 was expressed in bacteria in the E. coli BL21-PRIL strain (Stratagene) and purified on glutathione sepharose beads (Amersham-Pharmacia) as described . GST-parafibromin or GST-RPA2 conjugated to glutathione sepharose beads was incubated in thrombin cleavage buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2.5 mM CaCl2, and 1 mM DTT) with 10 U of thrombin (Sigma) per mg of GST-fusion protein to remove the GST tag. Thrombin was inactivated by adding a protease inhibitor cocktail (Roche Biochemicals) and 1 mM PMSF. The supernate containing parafibromin or RPA2, after thrombin cleavage, was passed through a benzamidine-sepharose column to remove the thrombin. The flowthrough was concentrated with an Amicon-50 (parafibromin) or an Amicon-10 (RPA2) concentrator. To obtain GST protein, glutathione sepharose beads loaded with GST were eluted with 50 mM Tris-HCl (pH 8) containing 10 mM reduced glutathione. To maintain similar treatment conditions GST was also incubated with thrombin, then with protease inhibitors, passed through a benzamidine-sepharose column, and concentrated with an Amicon-10 concentrator.
Low speed actin sedimentation assays used the Actin binding protein Biochem kit as per the manufacturer (Cytoskeleton). Briefly, rabbit skeletal muscle G-actin (monomeric globular actin) was polymerized to F-actin (polymerized filamentous actin). F-actin (36 μg) was mixed with actinin (10 μg) or parafibromin (4 μg) or GST (4 μg) or RPA2 (4 μg) or with thrombin cleavage buffer alone, or with actinin and parafibromin, or with actinin and GST, or with actinin and RPA2, and centrifuged at 10,000 g at room temperature for 15 minutes. The supernate was removed carefully and mixed with 12 μl of 5× protein loading buffer (supernatant fraction). The pellet was resuspended in 60 μl of 1× protein loading buffer (pellet fraction). 20 μl of the pellet fraction and 20 μl of the supernatant fraction were analyzed by SDS-PAGE, and the proteins were detected by Coomassie Blue.
Cells (HeLa, HEK293 or C2C12) were seeded on two-well chamber slides in complete DMEM and incubated overnight. To obtain differentiated C2C12 myotubes, sub-confluent cells were grown in differentiation medium for 4–6 days. Cells on chamber slides were fixed in PBS containing 4% paraformaldehyde for 20–30 minutes at room temperature and permeabilized with PBS containing 0.5% Triton X-100 for 5 minutes at room temperature. Conventional immunofluorescence was carried out as described . Microscopy and photomicrography was performed with an epifluorescence microscope (Zeiss).
The authors thank Dr. Neal Epstein for antibodies against actinin-2 and actinin-3, Dr. Erica Golemis for the yeast strain EGY48, and Dr. Christian Mosimann for the yeast two-hybrid constructs pCM031 and pRH95.
This study was supported by the intramural program of the National Institute of Diabetes and Digestive and Kidney Diseases.
- Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Höög A, Heath H, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002, 32: 676-680. 10.1038/ng1048View ArticlePubMedGoogle Scholar
- Jackson CE, Norum RA, Boyd SB, Talpos GB, Wilson SD, Taggart RT, Mallette LE: Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990, 108: 1006-1012.PubMedGoogle Scholar
- Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ: Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine. 2002, 81: 1-26. 10.1097/00005792-200201000-00001View ArticlePubMedGoogle Scholar
- Villablanca A, Calender A, Forsberg L, Höög A, Cheng JD, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson AL, Delbridge L, Meyrier A, Proye C, Carpten JD, Teh BT, Robinson BG, Larsson C: Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet. 2004, 41: e32- 10.1136/jmg.2003.012369PubMed CentralView ArticlePubMedGoogle Scholar
- Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A: Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003, 349: 1722-1729. 10.1056/NEJMoa031237View ArticlePubMedGoogle Scholar
- Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT: HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003, 40 (9): 657-663. (Erratum in: J Med Genet 2004, 41:20)., 10.1136/jmg.40.9.657PubMed CentralView ArticlePubMedGoogle Scholar
- Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T, Morreau H: Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol. 2007, 67: 370-376. 10.1111/j.1365-2265.2007.02894.x.View ArticleGoogle Scholar
- Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H, Teh BT: Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004, 10: 6629-6637. 10.1158/1078-0432.CCR-04-0493View ArticlePubMedGoogle Scholar
- Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF: Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene. 2005, 24: 1272-1276. 10.1038/sj.onc.1208274View ArticlePubMedGoogle Scholar
- Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D, Krek W: The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol. 2005, 25: 5052-5060. 10.1128/MCB.25.12.5052-5060.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceição Pereira M, Davie MW, Dudley N, Leite V, Sadler GP, Seller A, Thakker RV: Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol. 2006, 64: 299-306. 10.1111/j.1365-2265.2006.02460.x.View ArticleGoogle Scholar
- Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ: Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006, 30: 1140-1149.View ArticlePubMedGoogle Scholar
- Porzionato A, Macchi V, Barzon L, Masi G, Iacobone M, Parenti A, Palù G, De Caro R: Immunohistochemical assessment of parafibromin in mouse and human tissues. J Anat. 2006, 209: 817-827. 10.1111/j.1469-7580.2006.00657.xPubMed CentralView ArticlePubMedGoogle Scholar
- Zhang C, Kong D, Tan MH, Pappas DL, Wang PF, Chen J, Farber L, Zhang N, Koo HM, Weinreich M, Williams BO, Teh BT: Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun. 2006, 350: 17-24. 10.1016/j.bbrc.2006.08.169View ArticlePubMedGoogle Scholar
- Hahn MA, Marsh DJ: Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene. 2005, 24: 6241-6248. (Erratum in: Oncogene 2007, 26:788)., 10.1038/sj.onc.1208778View ArticlePubMedGoogle Scholar
- Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF: Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res. 2007, 5: 183-193. 10.1158/1541-7786.MCR-06-0129View ArticlePubMedGoogle Scholar
- Hahn MA, Marsh DJ: Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett. 2007, 581: 5070-5074. 10.1016/j.febslet.2007.09.050View ArticlePubMedGoogle Scholar
- Shi X, Chang M, Wolf AJ, Chang CH, Frazer-Abel AA, Wade PA, Burton ZF, Jaehning JA: Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol. 1997, 17: 1160-1169.PubMed CentralPubMedGoogle Scholar
- Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH, Meyerson M: The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005, 25: 612-620. 10.1128/MCB.25.2.612-620.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu B, Zheng Y, Pham AD, Mandal SS, Erdjument-Bromage H, Tempst P, Reinberg D: Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell. 2005, 20: 601-611. 10.1016/j.molcel.2005.09.025View ArticlePubMedGoogle Scholar
- Adelman K, Wei W, Ardehali MB, Werner J, Zhu B, Reinberg D, Lis JT: Drosophila Paf1 modulates chromatin structure at actively transcribed genes. Mol Cell Biol. 2006, 26: 250-260. 10.1128/MCB.26.1.250-260.2006PubMed CentralView ArticlePubMedGoogle Scholar
- Mosimann C, Hausmann G, Basler K: Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell. 2006, 125: 327-341. 10.1016/j.cell.2006.01.053View ArticlePubMedGoogle Scholar
- Fields S, Song O: A novel genetic system to detect protein-protein interactions. Nature. 1989, 340: 245-246. 10.1038/340245a0View ArticlePubMedGoogle Scholar
- Chien CT, Bartel PL, Sternglanz R, Fields S: The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc Natl Acad Sci USA. 1991, 88: 9578-9582. 10.1073/pnas.88.21.9578PubMed CentralView ArticlePubMedGoogle Scholar
- Winder SJ, Ayscough KR: Actin-binding proteins. J Cell Sci. 2005, 118: 651-654. 10.1242/jcs.01670View ArticlePubMedGoogle Scholar
- Meyer RK, Aebi U: Bundling of actin filaments by alpha-actinin depends on its molecular length. J Cell Biol. 1990, 110: 2013-2024. 10.1083/jcb.110.6.2013View ArticlePubMedGoogle Scholar
- Blanchard A, Ohanian V, Critchley D: The structure and function of alpha-actinin. J Muscle Res Cell Motil. 1989, 10: 280-289. 10.1007/BF01758424View ArticlePubMedGoogle Scholar
- Cooper ST, Maxwell AL, Kizana E, Ghoddusi M, Hardeman EC, Alexander IE, Allen DG, North KN: C2C12 co-culture on a fibroblast substratum enables sustained survival of contractile, highly differentiated myotubes with peripheral nuclei and adult fast myosin expression. Cell Motil Cytoskeleton. 2004, 58: 200-211. 10.1002/cm.20010View ArticlePubMedGoogle Scholar
- Dixson JD, Forstner MJ, Garcia DM: The alpha-actinin gene family: a revised classification. J Mol Evol. 2003, 56: 1-10. 10.1007/s00239-002-2374-5View ArticlePubMedGoogle Scholar
- Otey CA, Carpen O: Alpha-actinin revisited: a fresh look at an old player. Cell Motil Cytoskeleton. 2004, 58: 104-111. 10.1002/cm.20007View ArticlePubMedGoogle Scholar
- Reichl EM, Robinson DN: Putting the brakes on cytokinesis with alpha-actinin. Dev Cell. 2007, 13: 460-462. 10.1016/j.devcel.2007.09.010View ArticlePubMedGoogle Scholar
- Virel A, Backman L: Molecular evolution and structure of alpha-actinin. Mol Biol Evol. 2004, 21: 1024-1031. 10.1093/molbev/msh094View ArticlePubMedGoogle Scholar
- Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, Yamada Y, Chiba H, Hirohashi S: Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol. 1998, 140: 1383-1393. (Erratum in: J Cell Biol 1998, 143:276)., 10.1083/jcb.140.6.1383PubMed CentralView ArticlePubMedGoogle Scholar
- Mills M, Yang N, Weinberger R, Woude Vander DL, Beggs AH, Easteal S, North K: Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet. 2001, 10: 1335-1346. 10.1093/hmg/10.13.1335View ArticlePubMedGoogle Scholar
- Witke W, Hofmann A, Köppel B, Schleicher M, Noegel AA: The Ca(2+)-binding domains in non-muscle type alpha-actinin: biochemical and genetic analysis. J Cell Biol. 1993, 121: 599-606. 10.1083/jcb.121.3.599View ArticlePubMedGoogle Scholar
- Beggs AH, Byers TJ, Knoll JH, Boyce FM, Bruns GA, Kunkel LM: Cloning and characterization of two human skeletal muscle alpha-actinin genes located on chromosomes 1 and 11. J Biol Chem. 1992, 267: 9281-9288.PubMedGoogle Scholar
- Maciver SK: Microfilament organization and actin-binding proteins. The Cytoskeleton. Edited by: Pryme Greewich CT. 1995, 1-24. London UK: JAI press.Google Scholar
- Miralles F, Visa N: Actin in transcription and transcription regulation. Curr Opin Cell Biol. 2006, 18: 261-266. 10.1016/j.ceb.2006.04.009View ArticlePubMedGoogle Scholar
- Fernandez AG, Gunsalus KC, Huang J, Chuang LS, Ying N, Liang HL, Tang C, Schetter AJ, Zegar C, Rual JF, Hill DE, Reinke V, Vidal M, Piano F: New genes with roles in the C. elegans embryo revealed using RNAi of ovary-enriched ORFeome clones. Genome Res. 2005, 15: 250-259. 10.1101/gr.3194805PubMed CentralView ArticlePubMedGoogle Scholar
- Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell. 1999, 96: 143-152. 10.1016/S0092-8674(00)80967-8View ArticlePubMedGoogle Scholar
- Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC: Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA. 1998, 95: 1630-1634. 10.1073/pnas.95.4.1630PubMed CentralView ArticlePubMedGoogle Scholar
- Sukhodolets KE, Hickman AB, Agarwal SK, Sukhodolets MV, Obungu VH, Novotny EA, Crabtree JS, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ: The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol Cell Biol. 2003, 23: 493-509. 10.1128/MCB.23.2.493-509.2003PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.